Moleculin Biotech, Inc.
MBRX
$2.34
-$0.10-4.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.59% | -1.15% | 1.31% | 3.51% | -4.22% |
| Depreciation & Amortization | -70.97% | -32.26% | -9.38% | -3.13% | -11.43% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.40% | -17.22% | -7.52% | -10.99% | -25.52% |
| Operating Income | -13.40% | 17.22% | 7.52% | 10.99% | 25.52% |
| Income Before Tax | 336.21% | -261.60% | -131.29% | -29.50% | 35.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 336.21% | -261.60% | -131.29% | -29.50% | 35.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 336.21% | -261.60% | -131.29% | -29.50% | 35.88% |
| EBIT | -13.40% | 17.22% | 7.52% | 10.99% | 25.52% |
| EBITDA | -13.79% | 17.16% | 7.51% | 11.03% | 25.57% |
| EPS Basic | 121.12% | 64.00% | 62.72% | 65.82% | 74.32% |
| Normalized Basic EPS | 121.27% | 64.00% | 62.72% | 65.82% | 74.32% |
| EPS Diluted | 121.12% | 64.00% | 62.72% | 65.82% | 74.32% |
| Normalized Diluted EPS | 121.27% | 64.00% | 62.72% | 65.82% | 74.32% |
| Average Basic Shares Outstanding | 1,010.62% | 904.17% | 520.27% | 279.11% | 149.81% |
| Average Diluted Shares Outstanding | 1,010.62% | 904.17% | 520.27% | 279.11% | 149.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |